Lumenis unveils OptiLIFT for lower lid laxity and impaired blinking
The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.
(Image credit: Lumenis)
Lumenis, creator of OptiLIGHT, has revealed a new addition to their portfolio: OptiLIFT, a noninvasive device that leverages Dynamic Muscle Stimulation (DMSt™) technology to tone facial muscles and improve lower lid laxity and thus impaired blinking. The device is now available in the United States and will follow in additional markets.1
OptiLIFT uses proprietary DMSt, which, as the name implies, stimulates muscles in the periorbital area with electrical impulses to tighten and tone. Over time, the muscle strengthens, improving function of the lower eyelid. The reduction in lid laxity was investigated in a recent clinical study, led by James Chelnis, MD, FACS, and the results showed 75% reduction in lid laxity, 70% improvement in blinking quality, and a 286% increase in tear breakup time following use of OptiLIFT.2
“Lower lid laxity affects a large number of patients and can play a significant role in creating ocular surface symptoms. Despite this, we have had very few options for addressing it effectively. OptiLIFT finally offers us a non-surgical solution that is effective and comfortable for patients, without any downtime,” Chelnis said in a new release. “Our clinical study revealed remarkable outcomes for patients that highlight the true value of OptiLIFT.”
(Image credit: Lumenis)
The overlap between aesthetics and eye care grows with OptiLIGHT, as many highlights of the device target skin care concerns as well as lid function. In addition to tightening and toning the periorbital muscles, the device’s radiofrequency component uses heat to stimulate collagen formation around the eyes.3 Additionally, aesthetic-minded eye care providers can select a microneedling upgrade to increase skin smoothness by up to 80% and triple hyaluronic acid production without downtime or numbing by delivering the treatment via ultrathin needles and doubled radiofrequency mechanism.4
Lower lid laxity is a natural part of the aging process, partially caused by the weakening of the orbicularis oculi muscle,5 but it may result in incomplete blinking, ocular symptoms, and aesthetic concerns. According to one study, more than 60% of patients with dry eye experience incomplete lid closure.6,7 Lumenis hopes to address this gap in the market with its latest device.
“We are proud to introduce OptiLIFT, a groundbreaking advancement that addresses a significant and unmet need for patients and practices,” Itay Mayer, Chief Commercial Officer, Lumenis, said in a press release. “OptiLIFT enables providers to address lower lid laxity and impaired blinking non-surgically, delivering meaningful results for patients while offering a unique opportunity for practice differentiation. We look forward to collaborating with providers to close the gap in their practices, bring this new solution to the market, and elevate patient care.”
Lumenis is exhibiting OptiLIGHT at Vision Expo East in Orlando, Florida, February 19-22, 2025; interested optometrists can learn more about the device or receive a trial treatment at the Lumenis booth, #F1829.
